Literature DB >> 12598253

Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans.

Martin Luginbühl1, Andrea Gerber, Thomas W Schnider, Steen Petersen-Felix, Lars Arendt-Nielsen, Michele Curatolo.   

Abstract

UNLABELLED: Adding a small dose of ketamine to opioids may increase the analgesic effect and prevent opioid-induced hyperalgesia and acute tolerance to opioids. In this randomized, double-blinded, placebo-controlled crossover study, we investigated the effect of remifentanil combined with small concentrations of ketamine on different experimental pain models. Pain detection thresholds to single and repeated IM electrical stimulation and to repeated transcutaneous electrical stimulation, pressure pain tolerance threshold, and sedative, respiratory, and cardiovascular side effects were assessed in 14 healthy volunteers. Saline, remifentanil alone, and remifentanil combined with ketamine at target plasma concentrations of 50 or 100 ng/mL were administered in four study sessions. The ketamine infusion was started after baseline testing at a constant target concentration. Remifentanil was started after testing with ketamine alone at an initial target concentration of 1 ng/mL and then increased to 2 ng/mL and decreased to 1 ng/mL. The last test series were started 10 min after discontinuation of remifentanil. Acute remifentanil-induced hyperalgesia and tolerance were detected only by the pressure pain test and were not suppressed by ketamine. Remifentanil alone induced significant analgesia with all pain tests. Ketamine further increased the remifentanil effect only on IM electrical pain. Remifentanil at a 2 ng/mL target concentration induced a slight respiratory depression that was antagonized by ketamine. We conclude that ketamine effects on opioid analgesia are pain-modality specific. IMPLICATIONS: Coadministration of ketamine and morphine for pain relief is still controversial. Our experimental pain study with volunteers showed that ketamine enhances opioid analgesia without increasing sedation and reduces respiratory depression. Opioid-induced hyperalgesia and tolerance were not affected by ketamine and depended on the type of nociceptive stimulus. This may explain the conflicting results on opioid tolerance in previous studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598253     DOI: 10.1213/01.ane.0000048086.58161.18

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  27 in total

1.  Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats.

Authors:  Hiroki Shikanai; Sachiko Hiraide; Hidekazu Kamiyama; Tsukasa Kiya; Koji Oda; Yoshikazu Goto; Yoshiki Yanagawa; Kei-ichi Shimamura; Yukiko Goda; Hiroko Togashi
Journal:  J Anesth       Date:  2013-10-11       Impact factor: 2.078

Review 2.  Analgesic therapy for major spine surgery.

Authors:  Varun Puvanesarajah; Jason A Liauw; Sheng-fu Lo; Ioan A Lina; Timothy F Witham; Allan Gottschalk
Journal:  Neurosurg Rev       Date:  2015-02-14       Impact factor: 3.042

3.  [Opioid-induced analgesia and hyperalgesia].

Authors:  W Koppert
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 4.  Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations.

Authors:  Caroline A Arout; Ellen Edens; Ismene L Petrakis; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 5.  [Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?].

Authors:  C Zöllner; M Schäfer
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

6.  Altered quantitative sensory testing outcome in subjects with opioid therapy.

Authors:  Lucy Chen; Charlene Malarick; Lindsey Seefeld; Shuxing Wang; Mary Houghton; Jianren Mao
Journal:  Pain       Date:  2009-02-23       Impact factor: 6.961

7.  Opiate-induced hypernociception and chemokine receptors.

Authors:  Fletcher White; Natalie Wilson
Journal:  Neuropharmacology       Date:  2009-07-15       Impact factor: 5.250

8.  Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling.

Authors:  Pilar Sánchez-Blázquez; María Rodríguez-Muñoz; Javier Garzón
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

Review 9.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 10.  A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.

Authors:  Guido van Amerongen; Matthijs W de Boer; Geert Jan Groeneveld; Justin L Hay
Journal:  Br J Clin Pharmacol       Date:  2016-07-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.